Duteplase

Duteplase is a thrombolytic agent, specifically a tissue plasminogen activator (tPA), used in the treatment of acute myocardial infarction (AMI) and pulmonary embolism. It is a recombinant form of human tPA, produced using recombinant DNA technology.

Mechanism of Action

Duteplase works by converting plasminogen to plasmin, an enzyme that breaks down fibrin, the main component of blood clots. This process, known as fibrinolysis, helps to dissolve the clot and restore blood flow to the affected area.

Indications

Duteplase is indicated for use in the treatment of acute myocardial infarction and pulmonary embolism. It is typically administered within a few hours of the onset of symptoms, as early intervention can significantly improve outcomes.

Contraindications

Duteplase is contraindicated in patients with a history of hemorrhagic stroke, recent major surgery, active internal bleeding, or severe uncontrolled hypertension. It should be used with caution in patients with a history of gastrointestinal bleeding or peptic ulcer disease.

Side Effects

Common side effects of duteplase include bleeding, hypotension, nausea, and vomiting. Serious side effects can include intracranial hemorrhage, allergic reactions, and reperfusion arrhythmias.

Drug Interactions

Duteplase can interact with other medications, including anticoagulants, antiplatelet drugs, and certain antihypertensives. These interactions can increase the risk of bleeding.

Dosage and Administration

The dosage of duteplase is based on the patient's weight. It is administered intravenously, usually over a period of 90 minutes.

See Also

• Thrombolytic therapy
• Acute myocardial infarction
• Pulmonary embolism